According to ImmuPharma, the study was designed to show safety and tolerability and assess the maximum tolerated dose of IPP-204106.
In the trial, the patients were dosed with an initial dose of 40mg/sq.m. or 1mg/kg and if stabilisation or improvement occurs, then patients continued treatment for an additional 4 sessions.
So far 6 patients have been dosed in the trial who are suffering from either breast cancer, lung cancer and bladder cancer and all with metastasis.
ImmuPharma intends to file a US IND in the next few months and commence a Phase IIb programme in the first half of 2011in patients with metastatic melanoma, glioblastoma, hormone-resistant prostate cancer and pancreatic cancer, which will be confirmed by additional preclinical data.